Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
J Transl Med. 2022 Aug 12;20(1):360. doi: 10.1186/s12967-022-03561-x.
Precision medicine incorporating genetic profiling is becoming a standard of care in medical oncology. However, in the field of radiation oncology there is limited use of genetic profiling and the impact of germline genetic biomarkers on radiosensitivity, radioresistance, or patient outcomes after radiation therapy is poorly understood. In HNSCC, the toxicity associated with treatment can cause delays or early cessation which has been associated with worse outcomes. Identifying potential biomarkers which can help predict toxicity, as well as response to treatment, is of significant interest.
Patients with HNSCC who received RT and underwent next generation sequencing of somatic tumor samples, transcriptome RNA-seq with matched normal tissue samples were included. Patients were then grouped by propensity towards increased late vs. early toxicity (Group A) and those without (Group B), assessed by CTCAE v5.0. The groups were then analyzed for association of specific germline variants with toxicity and clinical outcomes.
In this study we analyzed 37 patients for correlation between germline variants and toxicity. We observed that TSC2, HLA-A, TET2, GEN1, NCOR2 and other germline variants were significantly associated with long term toxicities. 34 HNSCC patients treated with curative intent were evaluated for clinical outcomes. Group A had significantly improved overall survival as well as improved rates of locoregional recurrence and metastatic disease. Specific variants associated with improved clinical outcomes included TSC2, FANCD2, and PPP1R15A, while the HLA-A and GEN1 variants were not correlated with survival or recurrence. A group of five HLA-DMA/HLA-DMB variants was only found in Group B and was associated with a higher risk of locoregional recurrence.
This study indicates that germline genetic biomarkers may have utility in predicting toxicity and outcomes after radiation therapy and deserve further investigation in precision radiation medicine approaches.
精准医学结合基因谱分析已成为肿瘤内科的标准治疗方法。然而,在放射肿瘤学领域,基因谱分析的应用有限,胚系遗传生物标志物对放射敏感性、放射抵抗性或放射治疗后患者结局的影响也知之甚少。在头颈部鳞状细胞癌(HNSCC)中,与治疗相关的毒性可能导致延迟或提前终止,这与结局较差有关。确定有助于预测毒性以及对治疗反应的潜在生物标志物具有重要意义。
本研究纳入了接受放射治疗并进行体细胞肿瘤样本下一代测序、匹配正常组织样本转录组 RNA-seq 的 HNSCC 患者。根据 CTCAE v5.0 评估,患者被分为晚期毒性增加倾向组(A 组)和无增加倾向组(B 组)。然后,对两组与毒性和临床结局相关的特定胚系变异进行分析。
在本研究中,我们分析了 37 例患者的胚系变异与毒性之间的相关性。我们观察到 TSC2、HLA-A、TET2、GEN1、NCOR2 和其他胚系变异与长期毒性显著相关。对 34 例接受根治性治疗的 HNSCC 患者进行了临床结局评估。A 组的总生存率以及局部区域复发和远处转移疾病的发生率均显著提高。与改善临床结局相关的特定变异包括 TSC2、FANCD2 和 PPP1R15A,而 HLA-A 和 GEN1 变异与生存率或复发率无关。一组仅在 B 组中发现的五个 HLA-DMA/HLA-DMB 变异与局部区域复发风险增加相关。
本研究表明,胚系遗传生物标志物可能有助于预测放射治疗后的毒性和结局,值得进一步研究以应用于精准放射医学方法。